NEXALIN TECHNOLOGY INC (NXL) Stock News

NASDAQ:NXL - US65345B2016 - Common Stock

1.02 USD

+0.29 (+39.73%)

Last: 8/22/2025, 10:22:59 PM

0.951 USD

-0.07 (-6.76%)

After Hours: 8/22/2025, 10:22:59 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NXL Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill - Mentions: MOVE RH W PN ...

News Image

Which stocks are moving after the closing bell on Friday?

a day ago - By: Chartmill - Mentions: OPEN AEMD APM UI ...

News Image

What's going on in today's session

a day ago - By: Benzinga - Mentions: CSCI EVOK ZYME APLT ...

12 Health Care Stocks Moving In Friday's After-Market Session

a day ago - By: Benzinga - Mentions: NBY EQ AEMD SLGL ...

12 Health Care Stocks Moving In Friday's Intraday Session

a day ago - By: Chartmill - Mentions: AEMD EQ APM ANTE ...

News Image

Friday's session: top gainers and losers

2 days ago - By: Chartmill - Mentions: MSN GRO WDAY EVOK ...

News Image

Thursday's after hours session: top gainers and losers

23 days ago - By: Nexalin Technology, Inc.

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives

23 days ago - By: Nexalin Technology, Inc.

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives

3 months ago - By: ACCESS Newswire - Mentions: FATN

Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

3 months ago - By: Nexalin Technology, Inc.

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3

3 months ago - By: Nexalin Technology, Inc.

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3

3 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data

3 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

4 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

5 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

5 months ago - By: Nexalin Technology, Inc.

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

5 months ago - By: Nexalin Technology, Inc.

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3